McKesson Corp. (MCK)

158.67
NYSE : Distribution Services
Prev Close 156.45
Day Low/High 155.10 / 159.07
52 Wk Low/High 112.60 / 172.18
Avg Volume 4.67M
Exchange NYSE
Shares Outstanding 161.85M
Market Cap 25.39B
EPS 5.00
P/E Ratio 31.43
Div & Yield 1.64 (1.04%)
ZBH's Big Unjustified Price Correction

ZBH's Big Unjustified Price Correction

Shares are trading at less than 12.5x 2017's EPS estimates and should rise soon.

Valeant Skyrockets on Rumored $10B Salix Sale

Valeant Skyrockets on Rumored $10B Salix Sale

Investors rush to buy the drugmaker's stock following chatter of a much-needed megadeal.

Cramer: How Bad Was Today? Let Us Count the Ways

Cramer: How Bad Was Today? Let Us Count the Ways

Today there was a virtual vacuum of good news in the stock market.

Jim Cramer Says Pricing Pressure is the Reason Not to Buy Valeant

Jim Cramer Says Pricing Pressure is the Reason Not to Buy Valeant

Jim Cramer says there are other reasons not to buy Valeant, other than the criminal investigation.

Morning Movers: PFE, K, VRX, AEP

Morning Movers: PFE, K, VRX, AEP

Pfizer shares were slipping after the drugmaker posted a premarket earnings whiff.

Valeant's Frightful Halloween

Valeant's Frightful Halloween

Troubled drug firm sheds 12% on fresh fraud news.

Cramer: Nike Is a Victim of Price Wars; There Will Be Others

Cramer: Nike Is a Victim of Price Wars; There Will Be Others

Look out below when it comes to margins, as the price wars extend to sneakers, drugs and others.

Trader's Daily Notebook: Uncertainty Leads to Assets' Repricing

Trader's Daily Notebook: Uncertainty Leads to Assets' Repricing

I continue to believe downside risks far outweigh the risks of a near-term rally.

Cramer: Investors Look at Merck, Wondering Why They Did Not Buy Qualcomm

Cramer: Investors Look at Merck, Wondering Why They Did Not Buy Qualcomm

In a "take no pain, take no prisoners" market, health care stocks languish.

Stocks Under $10 Portfolio: Tax-Loss Selling Weighs on Indices

Stocks Under $10 Portfolio: Tax-Loss Selling Weighs on Indices

We used this week's declines to add to our positions in Teligent, Builders FirstSource and Sonus Networks.

McKesson Shares Plunge on Drug Price Cuts

McKesson Shares Plunge on Drug Price Cuts

Shares of the drug distributor were falling sharply Friday.

Stressed Out: Valeant Shareholders Flee on McKesson Warning

Stressed Out: Valeant Shareholders Flee on McKesson Warning

The drugmaker's shares were hammered Friday on news that the industry is slashing prices.

Trending Tickers: HSY, RCL, MCK, VRX

Trending Tickers: HSY, RCL, MCK, VRX

Hershey shares got an early Halloween treat Friday after earnings topped analyst forecasts.

Jim Cramer Explains Why Health Care Stocks are Getting Slammed on Wall Street Today

Jim Cramer Explains Why Health Care Stocks are Getting Slammed on Wall Street Today

McKesson's disappointing earnings report ignited a selloff in health care stocks, and Jim Cramer says investors are questioning the sector's future.

Jim Cramer: Healthcare Stocks in Crosshairs

Jim Cramer: Healthcare Stocks in Crosshairs

The pricing structure of the healthcare and drug distribution industry has been wrecked and Wall Street is taking down those stocks as a result, says Jim Cramer.

McKesson downgraded at Deutsche

McKesson downgraded at Leerink

Bullish & Bearish Reversals for the Week

Bullish & Bearish Reversals for the Week

Energy and consumer defensive names dominate on the bearish side.

McKesson's Correction Is not Just a Third-Quarter Issue

McKesson's Correction Is not Just a Third-Quarter Issue

Keep your powder dry and see if MCK tries to makes a double bottom.

McKesson downgraded at Goldman

Ignore the Political Debate and Buy These 4 Cheap Pharma Stocks

Ignore the Political Debate and Buy These 4 Cheap Pharma Stocks

McKesson is down 10 percent year-to-date due to the heated political debate over drug pricing but the stock is too cheap to ignore.

Cramer: The Answer to This Market: Part 1

Cramer: The Answer to This Market: Part 1

The leadership is quite stark.

'Timeliness' Isn't Always on Your Side

'Timeliness' Isn't Always on Your Side

In the case of McKesson, Value Line system doesn't do investors any favors.

Cramer: There Isn't Very Much to Buy, Despite the Dip

Cramer: There Isn't Very Much to Buy, Despite the Dip

There are issues everywhere, in almost every group.

When Covered Call Writing Makes Sense

When Covered Call Writing Makes Sense

The strategy doesn't deserve a lot of the criticism it gets.

Not Messin' With McKesson (Long)

Not Messin' With McKesson (Long)

Charts push for the short position.

It Looks Like McKesson Is Forming a Bottom

It Looks Like McKesson Is Forming a Bottom

But try to have your buy orders below the market, in the $165 area.

9 Health Names to Like Amid the Rhetoric

9 Health Names to Like Amid the Rhetoric

Candidates have decried rising drug and medical prices, but there are reasons to like these stocks.

McCormick Turns Up the Heat on Premier Foods

Undeterred by previous snubs, spicemaker McCormick makes a revised approach to Britain's Premier Foods, raising the proposed enterprise value to $2.16 billion.

Bearish Signals Are Rising

Bearish Signals Are Rising

The market went too far, too fast.